Skip to content
2000
image of Use of Any Form of Amphotericin B Alone or with Posaconazole in COVID-19 Associated Mucormycosis (CAM) at the Time of Pandemic Disaster in a Tertiary Care Teaching Hospital

Abstract

Background

The recent COVID-19 wave showed a significant rise in mucormycosis, changing its prevalence, particularly in India. Sadly, the total risk of mortality due to COVID-19 associated mucormycosis (CAM) remains high. It may be better to introduce a combination of drugs rather than unacceptable poor outcomes with Amphotericin B monotherapy.

Aim

The aim of this study is to assess the proportion of mucormycosis patient’s clinical outcomes with antifungal agent (Amphotericin B of any forms alone) or combination drug therapy (Amphotericin B of any form and Posaconazole).

Methods

It was a retrospective cohort study conducted between April 1st, 2021 and July 31st, 2021 at the tertiary care teaching hospital All India Institutes of Medical Sciences (AIIMS), Raipur.

Results

Out of 271 medical records of CAM patients, 211 records were included in the study. Among them, 46 patients (21.8%) received group 1 treatment . Amphotericin only and 165 patients (78.2%) received group 2 treatment, . Amphotericin B with Posaconazole. Group 2 was associated with a longer time to event, having a higher survival rate. The Hazard Ratio (HR) was 0.22 (95% CI – 0.13-0.36, -value 0.000).

Conclusion

Our findings will support the need for future studies to determine the efficacy of AMB and posaconazole combination therapy in the treatment of mucormycosis and to produce an evidence-based standard treatment regimen.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344355666250513101536
2025-05-15
2025-09-02

  • From This Site

    /content/journals/raaidd/10.2174/0127724344355666250513101536
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kwon-Chung K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis. 2012 54 1 S8 S15 10.1093/cid/cir864 22247451
    [Google Scholar]
  2. Jeong W. Keighley C. Wolfe R. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019 25 1 26 34 10.1016/j.cmi.2018.07.011 30036666
    [Google Scholar]
  3. Ibrahim AS Spellberg B Walsh TJ Kontoyiannis DP Pathogenesis of mucormycosis. Clin Infect Dis 2012 54 Suppl 1)(Suppl. 1 S16 S22 10.1093/cid/cir865 22247441
    [Google Scholar]
  4. Vaughan C. Bartolo A. Vallabh N. Leong S.C. A meta‐analysis of survival factors in rhino‐orbital‐cerebral mucormycosis—has anything changed in the past 20 years? Clin. Otolaryngol. 2018 43 6 1454 1464 10.1111/coa.13175 29947167
    [Google Scholar]
  5. Banerjee M. Pal R. Bhadada S.K. Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad. Med. J. 2022 98 e2 e108 e109 10.1136/postgradmedj‑2021‑140537 37066526
    [Google Scholar]
  6. John T.M. Jacob C.N. Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J. Fungi (Basel) 2021 7 4 298 10.3390/jof7040298 33920755
    [Google Scholar]
  7. Nithyanandam S. Jacob M.S. Battu R.R. Thomas R.K. Correa M.A. D’Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J. Ophthalmol. 2003 51 3 231 236 14601848
    [Google Scholar]
  8. Sharifi A. Akbari Z. Shafie’ei M. Retrobulbar injection of amphotericin b in patients with COVID-19 associated orbital mucormycosis: A systematic review. Ophthal. Plast. Reconstr. Surg. 2022 38 5 425 432 10.1097/IOP.0000000000002256 35943425
    [Google Scholar]
  9. Sarda R. Swain S. Ray A. Wig N. COVID-19-associated mucormycosis: An epidemic within a pandemic. QJM 2021 114 6 355 356 10.1093/qjmed/hcab165 34109406
    [Google Scholar]
  10. Prakash H. Chakrabarti A. Global epidemiology of mucormycosis. J. Fungi (Basel) 2019 5 1 26 10.3390/jof5010026 30901907
    [Google Scholar]
  11. Fortun J. Gioia F. Cardozo C. Posaconazole salvage therapy: The Posifi study. Mycoses 2019 62 6 526 533 10.1111/myc.12911 30864238
    [Google Scholar]
  12. Rosario D.K.A. Mutz Y.S. Bernardes P.C. Conte-Junior C.A. Relationship between COVID-19 and weather: Case study in a tropical country. Int. J. Hyg. Environ. Health 2020 229 113587 10.1016/j.ijheh.2020.113587 32917371
    [Google Scholar]
  13. Spellberg B. Walsh T.J. Kontoyiannis D.P. Edwards J. Jr Ibrahim A.S. Recent advances in the management of mucormycosis: From bench to bedside. Clin. Infect. Dis. 2009 48 12 1743 1751 10.1086/599105 19435437
    [Google Scholar]
  14. AL-Khikani FO. Amphotericin B as antiviral drug: Possible efficacy against COVID-19. Ann. Thorac. Med. 2020 15 3 118 124 10.4103/atm.ATM_147_20 32831932
    [Google Scholar]
  15. Garg D. Muthu V. Sehgal I.S. Coronavirus disease (COVID-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021 186 2 289 298 10.1007/s11046‑021‑00528‑2 33544266
    [Google Scholar]
  16. Kayarat B. Khanna P. Posaconazole in the prevention of COVID-19-associated mucormycosis: A concerning contributor to the rise in antifungal resistance. Indian J. Crit. Care Med. 2021 25 10 1209 1210 34916761
    [Google Scholar]
  17. Rodríguez M.M. Serena C. Mariné M. Pastor F.J. Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 2008 52 10 3786 3788 10.1128/AAC.00628‑08 18694953
    [Google Scholar]
  18. Luo G. Gebremariam T. Lee H. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob. Agents Chemother. 2013 57 7 3340 3347 10.1128/AAC.00313‑13 23650163
    [Google Scholar]
  19. Dravid A. Kashiva R. Khan Z. Epidemiology, clinical presentation and management of COVID‐19 associated mucormycosis: A single centre experience from Pune, Western India. Mycoses 2022 65 5 526 540 10.1111/myc.13435 35212032
    [Google Scholar]
  20. Reed C. Bryant R. Ibrahim A.S. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 2008 47 3 364 371 10.1086/589857 18558882
    [Google Scholar]
  21. Hinduja A.R.A. Tambe R.R. Giri P.A. Sunil S. Limaye H. Kalpana G. Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study. J. Family Med. Prim. Care 2022 11 10 6107 6114 10.4103/jfmpc.jfmpc_291_22 36618183
    [Google Scholar]
  22. Cornely O.A. Maertens J. Bresnik M. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 2007 44 10 1289 1297 10.1086/514341 17443465
    [Google Scholar]
  23. Thangaraju P. Tanguturi Yella S.S. Arumugam R.V. Is daclatasvir a suitable substitute for amphotericin b in the treatment of mucormycosis when amphotericin B is scarce? Curr. Drug Res. Rev. 2023 16 1 5 10 10.2174/2589977515666230430004013 37125653
    [Google Scholar]
  24. Samandar F. Amiri Tehranizadeh Z. Saberi M.R. Chamani J. 1,2,3,4,6-Pentagalloyl glucose of Pistacia lentiscus can inhibit the replication and transcription processes and viral pathogenesis of SARS-COV-2. Mol. Cell. Probes 2022 65 101847 10.1016/j.mcp.2022.101847 35843391
    [Google Scholar]
  25. Noor H. Ikram A. Rathinavel T. Kumarasamy S. Nasir Iqbal M. Bashir Z. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 – a computational modeling. J. Biomol. Struct. Dyn. 2022 40 13 5769 5784 10.1080/07391102.2021.1873190 33491580
    [Google Scholar]
  26. Clinical trial registry of India (CLTRI) 2023 Available from: https://ctri.nic.in/Clinicaltrials/advsearch2.php Accessed on: 20, Sep 2023).
  27. Dhakal A. Pokharel M. Madhup S. Khadka L. Sapkota B. Rhino-orbital mucormycosis in a COVID-19 patient: A dreadful challenge. Kathmandu Univ. Med. J. 2022 20 2 249 251 10.3126/kumj.v20i2.51465 37017177
    [Google Scholar]
  28. Salmanton-García J. Seidel D. Koehler P. Matched-paired analysis of patients treated for invasive mucormycosis: Standard treatment versus posaconazole new formulations (MoveOn). J. Antimicrob. Chemother. 2019 74 11 3315 3327 10.1093/jac/dkz344 31393591
    [Google Scholar]
  29. Manesh A. Devasagayam E. Bhanuprasad K. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: A prospective cohort study. Clin. Microbiol. Infect. 2023 29 10 1298 1305 10.1016/j.cmi.2023.06.017 37348653
    [Google Scholar]
  30. Cacciapuoti A. Gurnani M. Halpern J. Norris C. Patel R. Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob. Agents Chemother. 2005 49 2 638 642 10.1128/AAC.49.2.638‑642.2005 15673745
    [Google Scholar]
/content/journals/raaidd/10.2174/0127724344355666250513101536
Loading
Use of Any Form of Amphotericin B Alone or with Posaconazole in COVID-19 Associated Mucormycosis (CAM) at the Time of Pandemic Disaster in a Tertiary Care Teaching Hospital
Bentham Science Publishers ; https://doi.org/10.2174/0127724344355666250513101536
/content/journals/raaidd/10.2174/0127724344355666250513101536
/content/journals/raaidd/10.2174/0127724344355666250513101536
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Amphotericin B ; posaconazole ; COVID-19-associated mucormycosis ; antifungal ; SARS-CoV-2 ; black fungus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test